These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 19771564

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.
    Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G.
    Am J Hematol; 2005 Aug; 79(4):319-28. PubMed ID: 16044444
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. AH amyloidosis associated with an immunoglobulin heavy chain variable region (VH1) fragment: a case report.
    Miyazaki D, Yazaki M, Gono T, Kametani F, Tsuchiya A, Matsuda M, Takenaka Y, Hosh Y, Ikeda S.
    Amyloid; 2008 Jun; 15(2):125-8. PubMed ID: 18484339
    [Abstract] [Full Text] [Related]

  • 27. Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability.
    Bellotti V, Mangione P, Merlini G.
    J Struct Biol; 2000 Jun; 130(2-3):280-9. PubMed ID: 10940232
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains.
    Martin DJ, Ramirez-Alvarado M.
    Amyloid; 2010 Sep; 17(3-4):129-36. PubMed ID: 21077798
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.
    Morgan GJ, Kelly JW.
    J Mol Biol; 2016 Oct 23; 428(21):4280-4297. PubMed ID: 27569045
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Cell Damage in Light Chain Amyloidosis: FIBRIL INTERNALIZATION, TOXICITY AND CELL-MEDIATED SEEDING.
    Marin-Argany M, Lin Y, Misra P, Williams A, Wall JS, Howell KG, Elsbernd LR, McClure M, Ramirez-Alvarado M.
    J Biol Chem; 2016 Sep 16; 291(38):19813-25. PubMed ID: 27462073
    [Abstract] [Full Text] [Related]

  • 35. Immunoglobulin allotypes are not involved in systemic amyloidosis.
    Ockhuizen T, Westra H, Bijzet J, Post J, van Leeuwen M, van Rijswijk M.
    J Rheumatol; 1985 Aug 16; 12(4):742-6. PubMed ID: 3932652
    [Abstract] [Full Text] [Related]

  • 36. Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.
    Andrich K, Hegenbart U, Kimmich C, Kedia N, Bergen HR, Schönland S, Wanker E, Bieschke J.
    J Biol Chem; 2017 Feb 10; 292(6):2328-2344. PubMed ID: 28031465
    [Abstract] [Full Text] [Related]

  • 37. Amyloid fibril protein of light chain type from the muscle in a patient with amyloidosis.
    Isobe T, Imura H, Miyazaki K.
    Nihon Ketsueki Gakkai Zasshi; 1976 Jun 10; 39(3):329-30. PubMed ID: 824926
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Recurrent cardiac amyloidosis following previous heart transplantation.
    Luk A, Ahn E, Lee A, Ross HJ, Butany J.
    Cardiovasc Pathol; 2010 Jun 10; 19(4):e129-33. PubMed ID: 19740680
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.